Zelasudil

Overview

Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 ( ROCK2 ) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > ROCK

Product Information

• Catalog No.: HY-148808
• CAS No.: 2365193-22-0
• Molecular Formula: C22H21F2N7O
• Molecular Weight: 437.45
• Purity: 99.48%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (5.71 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source